Ana De Jesus-Acosta

Assistant Professor

20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Ana De Jesus-Acosta is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
  • Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study

    Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., de Jesus-Acosta, A., Delord, J. P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., Piha-Paul, S. A., Doi, T., Gao, B., Chung, H. C., Lopez-Martin, J., Bang, Y. J., Frommer, R. S., Shah, M., Ghori, R., Joe, A. K. & 2 others, Pruitt, S. K. & Diaz, L. A., 2020, In : Journal of Clinical Oncology. 38, 1, p. 1-10 10 p.

    Research output: Contribution to journalArticle

  • Effect of Gemcitabine and nab-Paclitaxel with or Without Hydroxychloroquine on Patients with Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial

    Karasic, T. B., O'Hara, M. H., Loaiza-Bonilla, A., Reiss, K. A., Teitelbaum, U. R., Borazanci, E., De Jesus-Acosta, A., Redlinger, C., Burrell, J. A., Laheru, D. A., Von Hoff, D. D., Amaravadi, R. K., Drebin, J. A. & O'Dwyer, P. J., Jul 2019, In : JAMA Oncology. 5, 7, p. 993-998 6 p.

    Research output: Contribution to journalArticle

  • Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

    De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Nv, R. K., Yabuuchi, S., de Wilde, R. F., Batukbhai, B., Sahin, I. & Laheru, D. A., Jan 1 2019, (Accepted/In press) In : British Journal of Cancer.

    Research output: Contribution to journalArticle